Allergan Plc (AGN)

160.60
3.50 2.20
NYSE : Health Technology
Prev Close 157.12
Open 157.53
Day Low/High 157.53 / 161.40
52 Wk Low/High 142.81 / 256.80
Volume 3.26M
Avg Volume 3.22M
Exchange NYSE
Shares Outstanding 345.73M
Market Cap 54.25B
EPS -13.20
P/E Ratio N/A
Div & Yield 2.88 (1.76%)

Latest News

Following Up on 3M

We believe that today's heavy selloff is an overreaction.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Weekly Roundup

Markets give up some gains Thursday and Friday, ahead of heavy earnings next week.

Some Biotech Stocks to Add Exposure To

Some Biotech Stocks to Add Exposure To

Secondary offerings create buying opportunities.

Allergan Showcases Leadership In Neurosciences With 25 Presentations At The American Academy Of Neurology Annual Meeting In Los Angeles

-- Phase 3 Oral CGRP Results for Ubrogepant Accepted as Late Breaker Emerging Science Presentation --

Jim's Daily Rundown

Jim discusses earnings from Nucor and Danaher, recent headlines about Apple, Amazon, Allergan, and more!

Revance Therapeutics Stock Looks Ready for New Gains

Revance Therapeutics Stock Looks Ready for New Gains

I don't understand the fundamentals but I find the chart interesting.

Technology Is Fueling Gains: Cramer's 'Mad Money' Recap (Wednesday 4/18/18)

Technology Is Fueling Gains: Cramer's 'Mad Money' Recap (Wednesday 4/18/18)

How do you get a stock moving? Jim Cramer says the answer is to invest in technology.

Revance Therapeutics: Cramer's Top Takeaways

Revance Therapeutics: Cramer's Top Takeaways

Dan Browne, co-founder, president and CEO of Revance Therapeutics, tells Jim Cramer his company is developing an alternative to Botox.

Jim's Daily Rundown

Today, Jim discusses Raytheon, tensions in Syria, bank earnings, Kohl's, Nordstrom and more!

Weekly Roundup

The markets bounced back on easing trade tensions and the banks kicked off first-quarter earnings season.

Mylan Spotlights Diversification at Investor Day

Mylan Spotlights Diversification at Investor Day

The drug company generates about 60% of revenue outside the U.S.

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

While more than half the states in the U.S. have passed time limits on opioid prescription as a way to battle the epidemic, the AMA says that should be left up to the doctor and patient.

Biosimilar Pipeline Among Areas of Shareholder Focus at Mylan's Investor Day

Biosimilar Pipeline Among Areas of Shareholder Focus at Mylan's Investor Day

The pharmaceutical firm will conduct its investor day in New York City on April 11.

McKesson Lawsuit Puts Drug Distributors Back Into Harsh Public Spotlight

McKesson Lawsuit Puts Drug Distributors Back Into Harsh Public Spotlight

McKesson and other drug distributors are having a difficult time steering clear of controversy, with the latest blow a lawsuit alleging McKesson has violated the False Claims Act.

Aegon Prices USD 800 Million Of Tier 2 Subordinated Debt

Aegon Prices USD 800 Million Of Tier 2 Subordinated Debt

Aegon has successfully priced USD 800 million Tier 2 subordinated debt securities, first callable on April 11, 2028, and maturing on April 11, 2048.

Aegon Completes Sale Of Aegon Ireland

Aegon Completes Sale Of Aegon Ireland

Today, Aegon has successfully completed the sale of Aegon Ireland plc to Athora Holding Ltd.

Initiating Position in UnitedHealth; Adding to 3M and Abbott Labs

We have long been fans of UNH as the company is a strong defensive name.

Trimming Allergan; Buying More Goldman Sachs

We will sell more AGN, consistent with our Three rating, and continue to scale into GS.

Weekly Roundup

Fears of a trade war and a Fed rate hike marked a volatile week.

Aegon Publishes 2017 Annual Report And Review

Aegon Publishes 2017 Annual Report And Review

Aegon N.V.

Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin®) For The Treatment Of Three Types Of Cancer

Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin®) For The Treatment Of Three Types Of Cancer

Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab)

Thursday's Selloff and How We Prepared for This Market

We are not jumping up and down to put capital to work, but when we see things we like, we will buy them in increments.

Adding to 3M and Comcast

We'll take advantage of this opportunity to buy on weakness with our healthy cash position.

Trump Opioid Policy Rollout Includes Call for Death Penalty for Dealers

Trump Opioid Policy Rollout Includes Call for Death Penalty for Dealers

President Trump made a long-awaited announcement of his administration's opioid plan in a New Hampshire speech that was part policy roll out and part political rally.

Markets Pressured in Today's Session

Notable weakness is coming from the FANG leadership group, which is being weighed down by heavy losses in Facebook.

TheStreet Quant Rating: D+ (Sell)